Company Northwest Biotherapeutics, Inc. Other OTC
Equities
NWBO
US66737P6007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +14.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Linda Powers
CEO | Chief Executive Officer | 68 | 17/07/17 |
Alton Boynton
FOU | Founder | 79 | 18/96/18 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/00/01 |
David Innes
IRC | Investor Relations Contact | - | 26/19/26 |
Leslie Goldman
LAW | General Counsel | 78 | 01/11/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alton Boynton
FOU | Founder | 79 | 18/96/18 |
Linda Powers
CEO | Chief Executive Officer | 68 | 17/07/17 |
Navid Malik
BRD | Director/Board Member | 55 | 01/12/01 |
Joseph Black
BRD | Director/Board Member | 74 | 27/16/27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,300,000 | 0 | 0 | 90.82 % |
Stock B | 1 | 1,208,177,416 | 1,097,287,981 ( 90.82 %) | 0 |
Company contact information
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 12TCr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr |